A
ADC Therapeutics SA D
D
ADCT
4.43000
USD
-0.16
(-3.49%)
مغلق
حجم التداول
13,521
الربح لكل سهم
-2
العائد الربحي
-
P/E
-3
حجم السوق
498,372,320
الأخبار المقالات
العنوان: ADC Therapeutics SA
القطاع: Healthcare
الصناعة: Biotechnology
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more linesof systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed byEurope, the Middle East and Africa (EMEA).